Involving providers in the development process of new reimbursement models increases the chance that the initiative will be successful and works against caregiver burnout, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.
Involving providers in the development process of new reimbursement models increases the chance that the initiative will be successful and works against caregiver burnout, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.
Transcript (slightly modified)
Should providers be involved in the development process of new reimbursement models?
I’m a crusader almost for the quadruple aim. Mostly everybody within healthcare, research, and healthcare policy understands the triple aim. The quadruple aim is additive to all the benefits of the triple aim. Quadruple aim, though, says exactly what your question implies: that we need to be including front-line caregivers when we’re designing these quality initiatives, whether it’s a CMS initiative, whether it’s a hospital initiative, or if you have a progressive group. If it’s an office-based quality improvement initiative, it’ll work umpteen times better if you include the front-line caregivers as early as you can in the design phase.
So, we’re doing that in Oklahoma. The 5 oncology practices that are part of OCM, we have brought together and we’re trying to make our own collaborative design for patients under 65 in Oklahoma, so we’ll see if it works. But, that’s precisely what we should be doing. Including the caregivers early on does 2 things: it increases the chance that the initiative will be successful, and it works against caregiver burnout, whether it’s a nurse or a doctor, pharmacist, or administrator, or lay caregivers who take care of our patients at home. We are all subject to burnout, and having caregivers as part of the design team lowers that risk.
Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS
April 11th 2025Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More